Intas pharmaceuticals limited is a leading, vertically integrated indian pharmaceutical company committed to delivering affordable and innovative pharmaceutical solutions. it is the largest privately owned generic pharmaceutical company in india. intas has been growing at about 27% cagr over the last several years and crossed the $1.7 billion mark in the past financial year. it is present in 70+ countries worldwide, with more than 60% of its revenue coming from global business, particularly the highly regulated markets of eu and us. the company has set up a network of subsidiaries, under the name accord healthcare, for marketing and selling in the highly regulated markets of eu, us, canada, south africa, australia, asia pacific as well as cis & mena regions. while intas has established leadership in key therapeutic segments like cns, cardiovascular, diabetology, gastroenterology, urology and oncology in india, the company is known for its range of products in oncology and other hospital-based therapeutic segments in the eu and us. intas is currently ranked 10th in the indian pharmaceutical market and one of the fastest growing players in india. intas is also one of the leading pharmaceutical conglomerates in the global stage, especially europe and the us. intas’ success and growth is a direct influence of intas’ extensive r&d and manufacturing capabilities. its strong r&d team consists of 200+ scientists supported by 350 analysts. intas possess a strategic pipeline of 300+ high-value ftf/ftm, biosimilars and ndds products. every year, the company invests ~6 - 7% of its revenues in r&d. currently, intas has over 10,000 product registrations worldwide. intas operates fourteen formulation manufacturing facilities, of which nine are located in india, and the rest in the u.k. and mexico. between them, the facilities are accredited by top global regulators such as usfda, ema, mhra, tga, and others.